Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines.

Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KH.

J Infect Dis. 2005 Nov 1;192(9):1628-33. Epub 2005 Sep 23.

PMID:
16206078
2.

Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.

Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, Matsui H, Hasegawa T, Maeyama J, Morokuma K, Ohkuma K, Tochikubo K.

Microbiol Immunol. 2008 Feb;52(2):55-63. doi: 10.1111/j.1348-0421.2008.00010.x.

3.

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.

Vaccine. 2006 May 1;24(18):3990-4006. Epub 2005 Dec 27.

PMID:
16516356
4.

Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy.

Yoshino N, Fujihashi K, Hagiwara Y, Kanno H, Takahashi K, Kobayashi R, Inaba N, Noda M, Sato S.

Vaccine. 2009 Jul 30;27(35):4808-17. doi: 10.1016/j.vaccine.2009.05.081. Epub 2009 Jun 17.

PMID:
19539583
5.

Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.

McNeal MM, Stone SC, Basu M, Bean JA, Clements JD, Hendrickson BA, Choi AH, Ward RL.

Virology. 2006 Mar 15;346(2):338-47. Epub 2006 Jan 10.

6.
7.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

8.

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.

Vaccine. 2006 Jan 30;24(5):544-51. Epub 2005 Aug 31.

PMID:
16169634
9.

Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.

Patel GB, Zhou H, Ponce A, Chen W.

Vaccine. 2007 Dec 12;25(51):8622-36. Epub 2007 Oct 5.

PMID:
17959279
10.

Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens.

Lee JB, Jang JE, Song MK, Chang J.

PLoS One. 2009;4(4):e5190. doi: 10.1371/journal.pone.0005190. Epub 2009 Apr 10.

11.

Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy.

Bade S, Baier M, Boetel T, Frey A.

Vaccine. 2006 Feb 27;24(9):1242-53. Epub 2006 Jan 13.

PMID:
16455168
12.

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.

Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam GB, Lycke NY.

J Gen Virol. 2008 Dec;89(Pt 12):2954-64. doi: 10.1099/vir.0.2008/005470-0.

PMID:
19008380
13.

Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.

McNeal MM, Basu M, Bean JA, Clements JD, Lycke NY, Ramne A, Löwenadler B, Choi AH, Ward RL.

Vaccine. 2007 Aug 14;25(33):6224-31. Epub 2007 Jun 21.

PMID:
17629371
14.

Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus.

Harakuni T, Kohama H, Tadano M, Uechi G, Tsuji N, Matsumoto Y, Miyata T, Tsuboi T, Oku H, Arakawa T.

Jpn J Infect Dis. 2009 Jan;62(1):37-45.

15.
16.

Antibody response in mice immunized by mucosal routes with formalin-inactivated enteropathogenic Escherichia coli (EPEC) strains.

Drago-Serrano ME, Manjarréz Hernandez HA, Gavilanes Parra S, Sainz Espuñes Tdel R.

Rev Latinoam Microbiol. 2004 Jan-Jun;46(1-2):17-23.

PMID:
17061522
17.

Nasal Administration of Cholera Toxin as a Mucosal Adjuvant Damages the Olfactory System in Mice.

Fukuyama Y, Okada K, Yamaguchi M, Kiyono H, Mori K, Yuki Y.

PLoS One. 2015 Sep 30;10(9):e0139368. doi: 10.1371/journal.pone.0139368. eCollection 2015.

18.

Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.

Skene CD, Doidge C, Sutton P.

Vaccine. 2008 Jul 23;26(31):3880-4. doi: 10.1016/j.vaccine.2008.05.004. Epub 2008 May 23.

PMID:
18547687
19.

Brain cytokine and chemokine mRNA expression in mice induced by intranasal instillation with ultrafine carbon black.

Tin-Tin-Win-Shwe, Yamamoto S, Ahmed S, Kakeyama M, Kobayashi T, Fujimaki H.

Toxicol Lett. 2006 May 25;163(2):153-60. Epub 2005 Nov 15.

PMID:
16293374
20.

Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice.

Huang CF, Wu TC, Chu YH, Hwang KS, Wang CC, Peng HJ.

Scand J Immunol. 2008 Nov;68(5):502-10. doi: 10.1111/j.1365-3083.2008.02172.x. Epub 2008 Sep 12.

Supplemental Content

Support Center